RT Journal Article
SR Electronic
T1 Genetic mechanisms of critical illness in Covid-19
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2020.09.24.20200048
DO 10.1101/2020.09.24.20200048
A1 Pairo-Castineira, Erola
A1 Clohisey, Sara
A1 Klaric, Lucija
A1 Bretherick, Andrew
A1 Rawlik, Konrad
A1 Parkinson, Nick
A1 Pasko, Dorota
A1 Walker, Susan
A1 Richmond, Anne
A1 Fourman, Max Head
A1 Russell, Clark D
A1 Law, Andrew
A1 Furniss, James
A1 Gountouna, Elvina
A1 Wrobel, Nicola
A1 Moutsianas, Loukas
A1 Wang, Bo
A1 Meynert, Alison
A1 Yang, Zhijian
A1 Zhai, Ranran
A1 Zheng, Chenqing
A1 Griffiths, Fiona
A1 Oosthuyzen, Wilna
A1 Grimes, Graeme
A1 Shih, Barbara
A1 Keating, Sean
A1 Zechner, Marie
A1 Haley, Chris
A1 Porteous, David J.
A1 Hayward, Caroline
A1 van Heel, David
A1 Barrett, Jeffery C
A1 Knight, Julian
A1 Summers, Charlotte
A1 Shankar-Hari, Manu
A1 Klenerman, Paul
A1 Turtle, Lance
A1 Ho, Antonia
A1 Hinds, Charles
A1 Horby, Peter
A1 Nichol, Alistair
A1 Maslove, David
A1 Ling, Lowell
A1 McAuley, Danny
A1 Montgomery, Hugh
A1 Walsh, Timothy
A1 ,
A1 Shen, Xia
A1 Rowan, Kathy
A1 Fawkes, Angie
A1 Murphy, Lee
A1 Ponting, Chris P.
A1 Tenesa, Albert
A1 Caulfield, Mark
A1 Scott, Richard
A1 Openshaw, Peter J.M.
A1 Semple, Malcolm G.
A1 Vitart, Veronique
A1 Wilson, James F.
A1 Baillie, J. Kenneth
YR 2020
UL http://medrxiv.org/content/early/2020/09/25/2020.09.24.20200048.abstract
AB The subset of patients who develop critical illness in Covid-19 have extensive inflammation affecting the lungs1 and are strikingly different from other patients: immunosuppressive therapy benefits critically-ill patients, but may harm some non-critical cases.2 Since susceptibility to life-threatening infections and immune-mediated diseases are both strongly heritable traits, we reasoned that host genetic variation may identify mechanistic targets for therapeutic development in Covid-19.3GenOMICC (Genetics Of Mortality In Critical Care, genomicc.org) is a global collaborative study to understand the genetic basis of critical illness. Here we report the results of a genome-wide association study (GWAS) in 2244 critically-ill Covid-19 patients from 208 UK intensive care units (ICUs), representing >95% of all ICU beds. Ancestry-matched controls were drawn from the UK Biobank population study.We identify and replicate three novel genome-wide significant associations, at chr19p13.3 (rs2109069, p = 3.98 × 10−12), within the gene encoding dipeptidyl peptidase 9 (DPP9), at chr12q24.13 (rs10735079, p = 1.65 × 10−8) in a gene cluster encoding antiviral viral restriction enzymes (OAS1, OAS2, OAS3), and at chr21q22.1 (rs2236757, p = 4.99 × 10−8) in the interferon receptor gene IFNAR2. Consistent with our focus on extreme disease in younger patients with less comorbidity, we detect a stronger signal at the known 3p21.31 locus than previous studies (rs73064425, p = 1.2 × 10−27).We identify potential targets for repurposing of licensed medications. Using Mendelian randomisation we found evidence in support of a causal link from low expression of IFNAR2, and high expression of TYK2, to life-threatening disease. Transcriptome-wide association in lung tissue revealed that high expression of the monocyte/macrophage chemotactic receptor CCR2 is associated with severe Covid-19.Our results identify robust genetic signals relating to key host antiviral defence mechanisms, and mediators of inflammatory organ damage in Covid-19. Both mechanisms may be amenable to targeted treatment with existing drugs. Large-scale randomised clinical trials will be essential before any change to clinical practice.Competing Interest StatementThe authors have declared no competing interest.Clinical Protocols https://genomicc.org/protocol/ Funding StatementGenOMICC was funded by Sepsis Research (the Fiona Elizabeth Agnew Trust), the Intensive Care Society, a Wellcome-Beit Prize award to J. K. Baillie (Wellcome Trust 103258/Z/13/A) and a BBSRC Institute Program Support Grant to the Roslin Institute (BBS/E/D/20002172). Whole-genome sequencing was done in partnership with Genomics England and was funded by UK Department of Health and Social Care, UKRI and LifeArc. ISARIC 4C is supported by grants from: the Medical Research Council [grant MC_PC_19059], the National Institute for Health Research (NIHR) [award CO-CIN-01] and by the NIHR Health Protection Research Unit (HPRU) in Emerging and Zoonotic Infections at University of Liverpool in partnership with Public Health England (PHE), in collaboration with Liverpool School of Tropical Medicine and the University of Oxford [award 200907], NIHR HPRU in Respiratory Infections at Imperial College London with PHE [award 200927], Wellcome Trust and Department for International Development [215091/Z/18/Z], and the Bill and Melinda Gates Foundation [OPP1209135], and Liverpool Experimental Cancer Medicine Centre (Grant Reference: C18616/A25153), NIHR Biomedical Research Centre at Imperial College London [IS-BRC-1215-20013], EU Platform foR European Preparedness Against (Re-) emerging Epidemics (PREPARE) [FP7 project 602525] and NIHR Clinical Research Network for providing infrastructure support for this research. PJMO is supported by a NIHR Senior Investigator Award [award 201385]. The views expressed are those of the authors and not necessarily those of the DHSC, DID, NIHR, MRC, Wellcome Trust or PHE. HM was supported by the NIHR BRC at University College London Hospitals. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Scotland 'A' research ethics committee (15/SS/0110), Coventry and Warwickshire research ethics committee (19/WM/0247).All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesSummary data will be available from the study website, https://genomicc.org/data and will be contributed to the Covid-19 human genetics innitiative. https://genomicc.org/data